GlaxoSmithKline Pharmaceuticals completes transaction with Novartis

~ Acquires the Vaccines business of Novartis
~ Divests its Oncology business to Novartis

GlaxoSmithKline Pharmaceuticals Ltd. (‘GSK India’) announces completion of its transaction with Novartis Healthcare Pvt. Ltd. (‘Novartis India’) today where GSK India acquires Novartis’ vaccines business and divests its marketed oncology portfolio to Novartis India.

This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.

The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK’s vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.

About GlaxoSmithKline:
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

GSK enquiries:
India Media enquiries: Ransom D’Souza +91 98202 34999 (Mumbai)
UK Media enquiries: Simon Steel +44 (0) 20 8047 5502 (London)